- IceCure exhibits and provides hands-on demonstrations at
SIO 2024 Annual Meeting in California, receiving enthusiastic response
from interventional oncologists
- ICE3 trial data were central to the
Breast Cryoablation Master Class taught by several ProSense®
users, including Dr. Tomkovich, ICE3's Co- Principal
Investigator, and Dr. Fine, ICE3 Investigator who has treated
numerous participants
CAESAREA, Israel, Jan. 29,
2024 /PRNewswire/ -- IceCure Medical Ltd.
(NASDAQ: ICCM) ("IceCure" or the "Company"), developer of the
ProSense® System, a minimally-invasive cryoablation technology that
destroys tumors by freezing as an alternative to surgical tumor
removal, today announced the Company is exhibiting and
conducting hands-on ProSense® demonstrations at the Society of
Interventional Oncology's ("SIO") Annual Scientific Meeting which
takes place from January 25-29, 2024
in Long Beach, California.
This year's SIO meeting featured an educational event, Breast
Cryoablation Master Class, the first of its kind by a radiology
society. Interventional oncologists attending the half-day course
learned from multidisciplinary experts in breast imaging, breast
surgery, interventional radiology, surgical oncology, medical
oncology, and radiation oncology. A literature review of notable
studies for breast cryoablation was presented, primarily including
interim data from IceCure's ICE3 breast cancer cryoablation study,
which demonstrated a 96.91% recurrence free rate. Master Class
teachers included Kenneth Tomkovich,
MD, ICE3's Co-Principal Investigator, Diagnostic and Interventional
Radiologist with Princeton Radiology, CentraState Medical Center,
and Penn Princeton Medical Center in Princeton, New Jersey; and ICE3 Investigator,
Richard Fine, MD, past President of
the American Society of Breast Surgeons, Program Director of the
Breast Surgical Oncology Fellowship, and Director of Research and
Education at the West Comprehensive Breast Center in Germantown, Tennessee.
"SIO 2024 marks a milestone for
breast cryoablation in the U.S. medical community as physicians
across disciplines from breast surgery to interventional
oncologists are looking to adopt cryoablation as a highly desirable
option for early stage breast cancer," stated IceCure CEO
Eyal Shamir. "We are pleased that
our interim ICE3 data provided highly meaningful insight and that
Drs. Tomkovich and Fine were available to provide guidance and best
practices to Master Class attendees. The reaction to ProSense® at
our booth was outstanding, and we are very optimistic about the
growing use of our cryoablation system in the U.S. where it has
regulatory clearance in many indications."
Dr. Tomkovich commented, "The Master Class, which was filled to
capacity, included interventional oncologists and breast
radiologists seeking education to build a successful breast
cryoablation program. As a radiologist and co-principal
investigator of the ICE3 study, I look forward to the presentation
of data from the full study population, which I believe will
provide even more evidence for physicians to adopt this minimally
invasive alternative."
Dr. Fine added, "I was happy to take part at the first SIO
Breast Cancer Cryoablation Master Class sharing my experience and
perspective as a breast surgeon. Breast cryoablation with ProSense®
is a minimally invasive, safe, fast, and painless
procedure. The interim data of the ICE3 trial results are
promising. The high level of interest in the procedure from
interventional oncologists and breast radiologists was
encouraging."
About ProSense®
The ProSense® Cryoablation System provides a minimally
invasive treatment option to destroy tumors by freezing them. The
system uniquely harnesses the power of liquid nitrogen to create
large lethal zones for maximum efficacy in tumor destruction in
benign and cancerous lesions, including breast, kidney, lung, and
liver.
ProSense® enhances patient and provider value by
accelerating recovery, reducing pain, surgical risks, and
complications. With its easy, transportable design and liquid
nitrogen utilization, ProSense® opens that door to fast and
convenient office-based procedure for breast tumors.
About IceCure Medical
IceCure Medical (NASDAQ: ICCM) develops and markets ProSense®,
an advanced liquid-nitrogen-based cryoablation therapy for the
treatment of tumors (benign and cancerous) by freezing, with the
primary focus areas being breast, kidney, bone and lung cancer. Its
minimally invasive technology is a safe and effective alternative
to hospital surgical tumor removal that is easily performed in a
relatively short procedure. The system is marketed and sold
worldwide for the indications cleared and approved to date
including in the U.S., Europe, and
China.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995 and other Federal
securities laws. Words such as "expects," "anticipates," "intends,"
"plans," "believes," "seeks," "estimates" and similar expressions
or variations of such words are intended to identify
forward-looking statements. For example, IceCure is using forward
looking statement in this press release when it discusses: that
physicians across disciplines from breast surgery to interventional
oncologists are looking to adopt cryoablation as a highly desirable
option for early stage breast cancer; the Company's optimism about
the growing use of its cryoablation system in the U.S. where it has
regulatory clearance in many indications; the belief that
cryoablation can be a superior option for the right early-stage
breast cancer patients; and that the Company's interim ICE3 trial
results are promising. Historical results of scientific research
and clinical and preclinical trials do not guarantee that the
conclusions of future research or trials will suggest identical or
even similar conclusions. Important factors that could cause actual
results, developments and business decisions to differ materially
from those anticipated in these forward-looking statements include,
among others: the Company's planned level of revenues and capital
expenditures; the Company's available cash and its ability to
obtain additional funding; the Company's ability to market and sell
its products; legal and regulatory developments in the United States and other countries; the
Company's ability to maintain its relationships with suppliers,
distributors and other partners; the Company's ability to maintain
or protect the validity of its patents and other intellectual
property; the Company's ability to expose and educate medical
professionals about its products; political, economic and military
instability in the Middle East,
specifically in Israel; as well as
those factors set forth in the Risk Factors section of the
Company's Annual Report on Form 20-F for the year ended
December 31, 2022 filed with the SEC
on March 29, 2023, and other
documents filed with or furnished to the SEC which are available on
the SEC's website, www.sec.gov. The Company undertakes no
obligation to update these statements for revisions or changes
after the date of this release, except as required by law.
IR Contact:
Email: investors@icecure-medical.com
Michael Polyviou
Phone: 732-232-6914
Todd Kehrli
Phone: 310-625-4462
Logo -
https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/icecure-medicals-breast-cryoablation-gains-prominence-in-the-us-as-society-of-interventional-oncology-annual-meeting-features-its-first-breast-cryoablation-master-class-302046623.html
SOURCE IceCure Medical